Table 1.
NP characteristics of the study population.
| NP4 score | 6.49 ± 1.54 | |
|
| ||
| Pain etiology | Diabetic neuropathy | 6 |
| Postherpetic pain | 11 | |
| Pain of rheumatic origin∗ | 32 | |
| Others∗∗ | 12 | |
| 7.57 ± 1.73 | ||
|
| ||
| Pain intensity according to EVA | Moderate intensity | 18 (29.5) |
| Severe intensity | 43 (70.5) | |
| Pain history | 2 years (min: 1 month; max: 25 years) | |
|
| ||
| Pain evolution | ≥6 months | 49 (80.3) |
| <6 months | 12 (12.7) | |
|
| ||
| Treatment | Without treatment | 20 (32.8) |
| With treatment | 40 (67.2) | |
| Treatment duration | 1.29 years (min: 0; max: 15 years) | |
|
| ||
| Number of treatments | Monotherapy | 13 (32.5) |
| Polytherapy (≥2 medicines) | 27 (67.5) | |
|
| ||
| Treatment nature | Morphine | 3 |
| Tramadol | 16 | |
| Paracetamol | 25 | |
| NSAIDs | 5 | |
| Tricyclic antidepressants | 17 | |
| New antiepileptics | 13 | |
| Classical antiepileptics | 3 | |
Mean ± standard deviation; ∗lumbosciatic, cervicobrachial neuralgia, carpal tunnel syndrome, and polyradiculopathy; ∗∗stroke, postsurgery, oncological, neuralgia of 6. NP4: Neuropathic Pain 4 questionnaire; VAS: Visual Analogic Scale; min: minimal value; max: maximal value, number (%); NSAI: nonsteroidal anti-inflammatory.